Pune court rejects 'Trademark-Violation Plea' filed against Serum SII over 'Covishield'

A local court in Pune on Saturday rejected injunction application filed on behalf of Cutish-Biotech against Serum Institute of India (SII), against use of 'Covishield' as brandname by vaccine-maker. While court order was t available immediately, lawyer of Cutis-Biotech, a pharmaceutical products manufacturer and seller based in Maharashtra, said it would file an appeal in high court.

This comes after, Cutis-Biotech, on January 4, filed a suit in civil court claiming that it was a prior use of brand name Covshield, and sought to restrain SII from using name. 

RE | Relief For SII As Court Rejects Tremark-violation Plea Over `Covishield'

Court rejects tremark-violation plea over Covishield

Giving out furr details of legal suit, SII's lawyer Hitesh Jain h told court that two companies operate in different product categories and re is scope for confusion over tremark. lawyer said, "Court has rejected application". Meanwhile, Cutis-Biotech lawyer itya Soni said that order copy was t yet available, but operative order was re out in court. Seeming unsatisfied with court's decision he said, "We will file an appeal against order in high court."

RE | Fire At Serum Institute Of India LIVE Updates: 5 De; SII Anunces Rs 25 Lakh Ex-gratia

Founded by Cyrus POonawalla in 1966, Serum Institute of India is  world's largest vaccine manufacturer and is located in Pune. Earlier in January first week, government of India has approved SII's Coronavirus vaccine named 'Covishield' and so far 11 million doses of vaccine have been purchased by government. 

(With PTI inputs)

RE | First Batch Of Covishield Vaccine Consignments Leave Pune's Serum Institute By Air & Ro

RE | India To Gift 2 Million Doses Of COVID Vaccine 'Covishield' To Banglesh On January 20